Get the Stockscreener App
2.44
2.01%
-0.05
After Hours:
2.41
-0.03
-1.23%
Moleculin Biotech Inc stock is traded at $2.44, with a volume of 132.54K.
It is down -2.01% in the last 24 hours and up +19.61% over the past month.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
See More
Previous Close:
$2.49
Open:
$2.44
24h Volume:
132.54K
Relative Volume:
0.85
Market Cap:
$13.02M
Revenue:
-
Net Income/Loss:
$-23.92M
P/E Ratio:
-0.0969
EPS:
-25.1834
Net Cash Flow:
$-22.74M
1W Performance:
+0.41%
1M Performance:
+19.61%
6M Performance:
-80.86%
1Y Performance:
-88.50%
1-Day Range:
$2.37
$2.46
1-Week Range:
$2.37
$2.77
52-Week Range:
$1.79
$28.61
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
2.44 | 13.29M | 0 | -23.92M | -22.74M | -25.18 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Resumed | H.C. Wainwright | Buy |
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Moleculin Biotech Stockholders Approve Warrant Share Issuance - TipRanks
Moleculin Biotech shareholders approve warrant issuance, reject name change By Investing.com - Investing.com India
Moleculin Biotech shareholders approve warrant issuance, reject name change - Investing.com
[EFFECT] Moleculin Biotech, Inc. SEC Filing - Stock Titan
[10-K/A] Moleculin Biotech, Inc. Amends Annual Report - Stock Titan
Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares via warrants - Stock Titan
Will Moleculin Biotech Inc benefit from geopolitical trends2026 Stock Rankings & Momentum Based Trading Ideas - baoquankhu1.vn
Momentum Shift: Will Moleculin Biotech Inc benefit from geopolitical trendsStop Loss & Technical Confirmation Trade Alerts - baoquankhu1.vn
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile - Sahm
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile - Bitget
MBRX Forecast, Price Target & Analyst Ratings | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Tangible book value per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech Stock: Advancing Cancer Therapies Amid Clinical Milestones and Biotech Volatility - AD HOC NEWS
Meme Stocks: What are Moleculin Biotech Incs earnings expectations2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
Moleculin Biotech files to sell 6.37M shares of common stock for holders - MSN
Total debt per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech Stock: Clinical-Stage Biotech Focused on Oncology Innovations for North American I - AD HOC NEWS
Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares tied to warrants - Stock Titan
Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga
MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - chartmill.com
Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Sell Signal: Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Moleculin at Roth Conference: Annamycin’s Market Potential By Investing.com - Investing.com Canada
Moleculin at Roth Conference: Annamycin’s Market Potential - Investing.com
MBRX: Annamycin's phase III AML trial nears key data, highlighting strong efficacy and zero cardiotoxicity - TradingView
MBRX: Annamycin's phase III AML trial nears key data, highlighting its efficacy and safety advantages - TradingView
MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus
Moleculin enrolls 45th patient in pivotal AML trial By Investing.com - Investing.com Canada
Moleculin Biotech Reports 40% Remission Rate in Early Phase 3 AML Study for Annamycin, Accelerating Toward 90 Patient Enrollment 12 - Minichart
Moleculin Biotech (MBRX) Advances Phase 2B/3 Trial for Acute Mye - GuruFocus
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - Bitget
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout - tipranks.com
Moleculin enrolls 45th patient in pivotal AML trial - investing.com
Moleculin Biotech, Inc. Prepares for Key Interim Results in Pivotal AML Trial with 40% Early Remission Rate - Quiver Quantitative
Moleculin Hits 45-Subject Milestone, Sets Mid-2026 MIRACLE Interim Readout - TradingView
Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial - Stock Titan
If You Invested $1,000 in Moleculin Biotec (MBRX) - Stock Titan
MBRX SEC FilingsMoleculin Biotec 10-K, 10-Q, 8-K Forms - Stock Titan
Moleculin Biotech, Inc.: Fundamental Analysis and Financial Ratings | MOL0 | US60855D4088 - marketscreener.com
MBRX Expects Cash Reserves to Fund Operations Through Q3 2026 - GuruFocus
Optimism Surrounds Moleculin's (MBRX) MIRACLE Trial Progress - GuruFocus
Moleculin Biotech Updates Investors with New Corporate Presentation - tipranks.com
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 - The Manila Times
Moleculin Biotech Reports 40% Preliminary CRc Rate in First 30 Patients of MIRACLE Trial for Relapsed/Refractory AML - Quiver Quantitative
[8-K] Moleculin Biotech, Inc. Reports Material Event - Stock Titan
Moleculin Biotech reports FY2025 net loss $33.6M, cash $8.9M; MIRACLE interim CRc 40% - TradingView
Moleculin's leukemia drug heads for a 45-patient readout in 2026 - Stock Titan
Moleculin (Nasdaq: MBRX) details 2025 loss and MIRACLE AML trial progress - Stock Titan
Moleculin Biotech 2025 Annual Report: Annamycin Clinical Trials & Pipeline Update - Minichart
Moleculin Biotech 10-K: No Revenue, Net Loss $33.6M, Ops Loss $25.1M - TradingView
Moleculin Biotech (NASDAQ: MBRX) outlines Annamycin Phase 3 AML strategy - Stock Titan
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):